Globus Medical, Inc. (NYSE:GMED) is expected to report third quarter earnings results, after market close, on Wednesday 28th October 2020.
Analysts polled by Thomson Reuters anticipate third quarter income of $ 0.30 per share.
Looking ahead, the full year income are expected at $ 1.13 per share on the revenues of $ 756.33 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 850.00 million ~ $ 850.00 million, where as bottomline are predicted in a range of $ 1.82 ~ $ 1.82 per share
Click Here For More Historical Outlooks Of Globus Medical, Inc.
Previous Quarter Performance
Globus Medical, Inc. disclosed income for the second quarter of $ 0.07 per share, from the revenue of $ 148.92 million. According to street consensus, GMED was expected to report 2Q20 loss of $ 0.11 per share from revenue of $ 99.73 million. The bottom line results beat street analysts by $ 0.18 or 163.64 percent, at the same time, top line results outshined analysts by $ 49.19 million or 49.32 percent.
Stock Performance
Shares of Globus Medical, Inc. traded low $ -2.51 or -4.67 percent on Tuesday, reaching $ 51.26 with volume of 441.90 thousand shares. Globus Medical, Inc. has traded high as $ 53.91 and has cracked $ 50.82 on the downward trend
According to the previous trading day, closing price of $ 51.26, representing a 60.94 % increase from the 52 week low of $ 33.41 and a 10.61 % decrease over the 52 week high of $ 60.15.
The company has a market capital of $ 5.01 billion and is part of the Healthcare sector and Medical Devices industry.
Conference Call
Globus Medical, Inc. will be hosting a conference call at 4:30 PM eastern time on 28th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.globusmedical.com
Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its spine product portfolio includes a range of implant and surgical approach options that could be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum.
